Traws Pharma Begins Phase 2 COVID-19 Treatment Study

The latest update is out from Traws Pharma ( (TRAW) ).

On October 14, 2025, Traws Pharma announced the dosing of the first subject in its Phase 2 study evaluating ratutrelvir, a ritonavir-free treatment for COVID-19. The study aims to compare ratutrelvir against PAXLOVID® and assess its safety and efficacy, including the potential to reduce disease rebound and Long COVID incidence. A separate trial will focus on PAXLOVID®-ineligible patients, a vulnerable group with limited treatment options. Results from both trials are expected by the end of 2025, which could significantly impact Traws Pharma’s position in the COVID-19 treatment market.

The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.

Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases, including COVID-19, Long COVID, bird flu, and seasonal influenza. The company integrates antiviral drug development, medical intelligence, and regulatory strategy to address real-world challenges, with products like ratutrelvir and tivoxavir marboxil in development.

Average Trading Volume: 153,195

Technical Sentiment Signal: Sell

Current Market Cap: $21.45M

See more data about TRAW stock on TipRanks’ Stock Analysis page.